EGFR and non-small cell lung carcinoma: Lastly, we highlight the available studies conducted to analyze the implications of body composition phenotypes on survival outcomes in patients with NSCLC who were treated with either EGFR TKI or ICI; we also provide our recommendations on the conceptual utility of incorporating body composition calculations into prospective trials.